Absorption in the Gut: Why Some Supplements Survive the Stomach and Others Don't

Oral absorption is not a single event — it is a sequence of barriers that each independently determine how much of a dose reaches systemic circulation.

**Barrier 1: Dissolution in the gut lumen.** Before any compound can be absorbed through the intestinal wall, it must dissolve in the fluid of the gut lumen. A compound that remains as solid particles cannot cross a membrane. Solubility is highly dependent on pH: the stomach is highly acidic (pH 1–3 in a fasting state), but the small intestine — where most mineral absorption occurs — rises to pH 5–7. Some inorganic mineral salts, including magnesium oxide and calcium carbonate, have much lower solubility at the higher pH of the small intestine than at the acidic pH of the stomach. If the mineral doesn't dissolve in the stomach before passing through to the small intestine, the fraction available for absorption is constrained.

**Barrier 2: Mucosal transporter access.** Once dissolved, the mineral ion must cross the intestinal epithelium — the single cell layer that separates the gut lumen from the portal bloodstream. Minerals can cross by passive diffusion (limited; follows concentration gradients) or via specific carrier proteins (transporter-mediated uptake). Active transporter pathways have finite capacity; at high enough doses, they become saturated, and additional mineral passes through unabsorbed. Inorganic mineral ions (Mg²⁺, Ca²⁺, Zn²⁺) compete for shared transporter slots. Amino acid chelates exploit a distinct pathway: because the mineral is bound to an amino acid, the whole complex enters via amino acid transporters — a system with substantially greater throughput capacity and less competition from co-ingested minerals.

**Barrier 3: First-pass conditions.** After crossing the gut wall, absorbed compounds enter the portal circulation and reach the liver. For some organic compounds, hepatic metabolism during this "first pass" reduces the fraction that reaches systemic circulation. For minerals, first-pass hepatic effects are less dominant, but the principle of sequential barriers applies broadly across supplement types.

The pH of the gastrointestinal tract varies substantially by location, and this variation has direct consequences for mineral supplements that depend on acid dissolution.

Gastric pH in a fasting state is typically 1–3. This highly acidic environment can dissolve inorganic mineral salts — including magnesium oxide — reasonably well. But gastric emptying moves contents into the duodenum and small intestine, where bicarbonate secretion raises pH to 5–7 or higher. This is the section where most mineral absorption actually occurs.

Magnesium oxide is a case study in what happens when dissolution depends on acidic conditions that aren't reliably present throughout the absorption zone. The molecule has low solubility at near-neutral pH. If it hasn't fully dissolved before gastric emptying, the solid particles pass into the small intestine where dissolution is limited — and so is absorption.

This effect is amplified in individuals with reduced gastric acid production (achlorhydria or hypochlorhydria), which is more prevalent in older adults and in users of proton pump inhibitors (a widely prescribed class of medications). For these individuals, the already-limited dissolution window in the stomach is further narrowed, and insoluble mineral forms may pass through the gut largely intact.

Organic salt forms — citrate, malate, glycinate — have substantially different solubility profiles. Mineral citrates and amino acid chelates remain more soluble across a wider pH range, maintaining availability for absorption throughout the small intestine rather than depending entirely on the acidic stomach window.

Magnesium has one of the most extensively documented form-specific absorption differences in the supplement literature, making it a useful illustration of the three barriers at work.

A 2001 crossover pharmacokinetic study by Firoz and Graber, published in Magnesium Research (PMID 11794633), measured the bioavailability of four commercially available magnesium preparations in 10 healthy adults. Bioavailability was assessed by measuring the increment in urinary magnesium excretion — a validated proxy for intestinal absorption, since magnesium is excreted proportionally to intake in individuals with normal renal function. The study found:

- Magnesium oxide: approximately 4% fractional absorption - Magnesium chloride, lactate, and aspartate: significantly higher bioavailability (statistically superior to oxide; p < 0.05), with equivalent absorption between the three organic forms

The difference is not explained by elemental content — magnesium oxide has one of the highest elemental percentages of any magnesium salt (approximately 60% by molecular weight). The difference is explained by dissolution and transporter access. At the pH conditions of the small intestine, the oxide form's low solubility limits the fraction of the dose available for absorption, while the organic salt forms remain more soluble and accessible to intestinal transporters.

The practical consequence: a consumer comparing a 500 mg magnesium oxide capsule against a 400 mg magnesium glycinate capsule based on the label numbers is evaluating the wrong variable. The effective absorbed dose from the oxide — despite the higher milligram count — may be substantially lower.

Work with your physician before adjusting magnesium supplementation, particularly if you are managing cardiovascular disease, kidney disease, or taking medications that affect electrolyte balance. These ingredients are not a substitute for professional medical advice, diagnosis, or treatment.

Calcium supplements follow a similar but instructive pattern, with a key additional factor: the pH-dependence of calcium carbonate absorption makes it particularly sensitive to gastric acid levels, which decline with age.

Calcium carbonate requires acidic conditions to dissolve effectively. When taken with a meal — which stimulates gastric acid secretion — carbonate can dissolve reasonably well. When taken in a fasting state, the limited acid production means carbonate may not fully dissolve before gastric emptying.

Calcium citrate has substantially different solubility characteristics. The citrate salt does not require an acidic environment to dissolve and maintains solubility across a broader pH range, including the near-neutral conditions of the small intestine.

A randomized crossover study by Heller et al., published in the Journal of Clinical Pharmacology in 2000 (PMID 11075309), compared single-dose bioavailability of calcium citrate (500 mg elemental Ca) versus calcium carbonate (500 mg elemental Ca) in 25 postmenopausal women, administered with a standard breakfast. Calcium citrate produced a 94% higher area under the serum calcium curve (AUC) and a 41% greater increment in urinary calcium — both statistically significant. The decrement in serum parathyroid hormone (a functional marker of absorbed calcium's biological effect) was also greater after citrate.

The implications for older adults are particularly relevant. As gastric acid production decreases with age, the acid-dependent dissolution window for calcium carbonate narrows further. For individuals over 50 — the age group most commonly recommended to supplement calcium — citrate's pH-independent solubility profile may offer a meaningful absorption advantage. In the Heller et al. study, that advantage was demonstrated when both forms were dosed with a meal.

When a mineral is bound to an amino acid in a chelate complex — magnesium glycinate, zinc picolinate, iron bisglycinate — it doesn't need to compete for the same mineral-ion transporter slots that inorganic ions use.

Standard mineral-ion transporters (e.g., DMT-1 for iron; shared divalent metal transporters for zinc, magnesium, and calcium) have finite capacity and are subject to competitive inhibition. When the gut lumen contains multiple divalent minerals at the same time — common when taking a multivitamin or a mineral-heavy meal — each ion competes with the others for the same limited transporter throughput. The amount absorbed per mineral is reduced.

Amino acid chelates exploit a different entry point. The mineral-amino acid complex enters the intestinal cell via amino acid transporters — systems with substantially higher throughput designed to handle the continuous dietary flow of amino acids. The chelate structure is intact until it crosses the mucosal barrier; once inside the enterocyte, the complex can be metabolized and the mineral enters the portal circulation.

This mechanism is documented in mechanistic and pharmacokinetic literature on mineral chelates and explains why chelated forms frequently show superior absorption in studies where the same elemental dose is compared. It is also why chelated forms are generally more expensive to manufacture: the synthesis step that bonds the mineral to the amino acid ligand adds process complexity and input cost.

The consumer typically sees none of this in the labeling — only the mineral name and a milligram count that measures the salt weight, not the absorbed fraction.

Enteric coating and sustained-release formulations are legitimate pharmaceutical technologies with specific applications — but they are also marketing narratives that can obscure rather than improve absorption.

**Enteric coating** is a pH-sensitive polymer coating applied to a tablet or capsule that is designed to remain intact in the acidic stomach and dissolve in the higher-pH small intestine. The legitimate application is protecting acid-sensitive compounds from stomach acid degradation, or reducing gastric irritation for compounds that cause nausea when dissolved in the stomach. For these applications, enteric coating serves a real pharmacological purpose.

The concern arises when enteric coating is used to create a "delayed release" narrative for mineral supplements where the actual goal is higher absorption. If the underlying mineral form has poor solubility at small intestine pH — as is the case for magnesium oxide — an enteric coating delivers an insoluble compound to an environment where it still won't dissolve well. The coating delays the problem; it doesn't solve the form-specific solubility issue.

**Sustained-release** typically refers to a matrix formulation that releases the mineral gradually as the tablet matrix erodes. For some minerals, gradual release can reduce the dose delivered to any single segment of gut at one time, potentially reducing laxative effects (relevant for magnesium) or reducing transporter saturation. Whether this translates to measurably higher total absorption depends on the specific mineral form and the formulation design.

The key signal when evaluating "enteric-coated" or "sustained-release" products is the underlying form. If the mineral salt itself has low solubility at the relevant gut pH, delivery technology cannot fully compensate. If the underlying form is already well-absorbed at standard gut pH, these coatings may offer marginal benefit. The label's delivery technology claim does not substitute for the form-specific absorption data.